State Supreme Court Rejects Challenge, Clearing Way for Stem Cell Bond Initiative
By Joyce E. Cutler,
Bureau of National Affairs
| 05. 17. 2007
The California Supreme Court refused May 16 to consider a constitutional challenge to the state stem cell initiative, clearing the way for $3 billion in bonds to be sold to fund stem cell research (People's Advocate and National Tax Limitation Foundation v. Independent Citizens Oversight Committee, Cal., No. S151574, review denied, 5/16/07).
Justices at their weekly meeting declined to review the appeal brought by opponents of California's Proposition 71, a November 2004 initiative authorizing an annual pool of $300 million to further stem cell and other medical research over a decade.
Justice Joyce Kennard voted to grant review of the decision by the California Court of Appeal, First District, upholding the initiative, according to the court docket.
A unanimous panel of the appeals court ruled last February, “we have no hesitation in concluding, in the exercise of 'our solemn duty to jealously guard the precious initiative power,’ that Proposition 71 suffers from no constitutional or other legal infirmity” (California Family Bioethics Council v. Independent Citizens' Oversight Committee, Cal. Ct. App., No. A114195; People's Advocate v. Independent Citizens' Oversight Committee, Cal...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...